Pharmaceuticals, Biotechnology and Life Sciences
Cancer Research UK’s Centre for Drug Development will fund Phase I clinical trial in solid tumours, Crescendo’s novel bispecific Humabody immunotherapies, CB213.
Crescendo Biologics has reached fifth milestone in its deal with Takeda from 2016, for using its Humabody-based therapeutics against targets which Takeda selects.
CAMBRIDGE, England–(BUSINESS WIRE)–Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T-cell enhancing therapeutics, today announces that Takeda Pharmaceutical…
Myriad Genetics’ study results on development of the adjusted Vectra, announced Wednesday, found it outperforming typical measures of disease activity in predicting new joint damage in rheumatoid arthritis patients.